**Question:** All of the following are tumor necrosis factor (TNF) inhibitors. Select the correct options:

A. Enbrel (Etanercept)
B. Remicade (Infliximab)
C. Kineret (Anakinra)
D. Humira (Adalimumab)

**Correct Answer:**

**Core Concept:**

Tumor necrosis factor (TNF) is a pro-inflammatory cytokine that plays a crucial role in autoimmune diseases and inflammatory conditions. TNF inhibitors are medications that block TNF activity to reduce inflammation and suppress the immune system.

**Why the Correct Answer is Right:**

Enbrel (Etanercept), Remicade (Infliximab), and Humira (Adalimumab) are all monoclonal antibodies that specifically target TNF-alpha, thereby inhibiting its activity and reducing inflammation.

**Why Each Wrong Option is Incorrect:**

Kineret (Anakinra) is a recombinant human IL-1 receptor antagonist, specifically targeting interleukin-1 (IL-1). Although it is an anti-inflammatory medication, it does not inhibit TNF-alpha, making it incorrect in this context.

**Clinical Pearl / High-Yield Fact:**

Understanding the role of TNF-alpha and its inhibitors is crucial in the management of autoimmune diseases like rheumatoid arthritis, ankylosing spondylitis, and Crohn's disease. A thorough knowledge of these medications can lead to improved patient outcomes and informed treatment decisions.

**Why Each Wrong Option is Incorrect:**

Option D, Humira (Adalimumab), is also a TNF inhibitor, but it is a monoclonal antibody directed against TNF-alpha, making it a correct choice.

Option C, Kineret (Anakinra), is an anti-inflammatory medication, but it does not inhibit TNF-alpha, making it incorrect in this context.

**Why Each Wrong Option is Incorrect:**

Option A, Enbrel (Etanercept), is a soluble receptor that binds to TNF-alpha, inhibiting its activity and reducing inflammation. This makes it a correct choice as well.

Option B, Remicade (Infliximab), is a monoclonal antibody that binds to TNF-alpha, inhibiting its activity and reducing inflammation. This makes it a correct choice as well.